Parexel’s consulting subsidiary Health Advances opens in Hong Kong to provide business strategy as well as scientific and clinical expertise to customers in the region.
AlzProtect is collaborating with Parexel Biotech to advance a Phase IIa clinical trial of its lead candidate, AZP2006, which is being developed for the treatment of a rare neurodegenerative disease.
Parexel Biotech will support emerging companies from development through commercialization with tailored services and customized guidance, says division lead.